Fresenius SE & Co. KGaA (ETR:FRE)
Germany · Delayed Price · Currency is EUR 48.97
-0.86 (-1.73%)
Jan 19, 2026, 1:39 PM CET
Fresenius SE & Co. KGaA Revenue
Fresenius SE & Co. KGaA had revenue of 5.49B EUR in the quarter ending September 30, 2025, with 3.20% growth. This brings the company's revenue in the last twelve months to 22.45B, up 4.49% year-over-year. In the year 2024, Fresenius SE & Co. KGaA had annual revenue of 21.83B with 3.64% growth.
Revenue (ttm)
22.45B
Revenue Growth
+4.49%
P/S Ratio
1.25
Revenue / Employee
126.55K
Employees
176,486
Market Cap
28.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21.83B | 766.00M | 3.64% |
| Dec 31, 2023 | 21.07B | -465.00M | -2.16% |
| Dec 31, 2022 | 21.53B | -15.99B | -42.61% |
| Dec 31, 2021 | 37.52B | 1.24B | 3.43% |
| Dec 31, 2020 | 36.28B | 868.00M | 2.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
| Carl Zeiss Meditec AG | 2.23B |
Fresenius SE & Co. KGaA News
- 4 days ago - Fresenius SE & Co KGaA at JPMorgan Healthcare Conference Transcript - GuruFocus
- 4 days ago - Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day - Slideshow - Seeking Alpha
- 6 weeks ago - DaVita: More Volatile But Better Upside Than Fresenius - Seeking Alpha
- 7 weeks ago - Fresenius Launches Denosumab Biosimilars - Nasdaq
- 2 months ago - EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 2 months ago - EQS-AFR: Fresenius SE & Co. KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online